# Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

> **NCT00112047** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 517 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Emtricitabine (FTC)
- **DRUG:** Tenofovir Disoproxil Fumarate (TDF)
- **DRUG:** Efavirenz (EFV)
- **DRUG:** FTC/TDF
- **DRUG:** FTC/TDF/EFV
- **DRUG:** Lamivudine/zidovudine

## Key facts

- **NCT ID:** NCT00112047
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-02
- **Final completion:** 2009-06
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2010-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112047, "Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00112047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*